ERBB2 and Langer mesomelic dysplasia: IT trastuzumab has been studied in patients with human epidermal growth factor receptor 2 (HER2) positive LMD [14–18], including in a recent prospective study in 34 patients with HER2 + MBC and MBC, demonstrating a median overall survival of 10.5 months [19].